



Spreading Knowledge – Improving Outcomes

Delirium Treatment



Treatment of Underlying Conditions

Metabolic
encephalopathy

Drug toxicity

Withdrawal
from alcohol
and sedatives

HALOPERIDOL & ANTIPYSCHOTICS USE IN THE PREVENTION & TREATMENT OF DELIRIUM IN THE ICU

Summary of Evidence



2018

MIND-USA

The use of haloperidol or ziprasidone, as compared with placebo, in patients with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not significantly alter the duration of delirium..



HALOPERIDOL & ANTIPSYCHOTICS USE IN THE PREVENTION & TREATMENT OF DELIRIUM IN THE ICU

Summary of Evidence



2018

MIND-USA

The use of haloperidol or ziprasidone, as compared with placebo, in patients with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not significantly alter the duration of delirium..



2019

PREVENTION

SYSTEMATIC REVIEW

Current evidence does not support routine use of haloperidol or second-generation antipsychotics for prevention of delirium. There is limited evidence that second-generation antipsychotics may lower the incidence of delirium in postoperative patients!

Annals of Internal Medicine®

HALOPERIDOL & ANTIPYSCHOTICS USE IN THE PREVENTION & TREATMENT OF DELIRIUM IN THE ICU

Summary of Evidence



2018

MIND-USA

The use of haloperidol or ziprasidone, as compared with placebo, in patients with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not significantly alter the duration of delirium..



2019

PREVENTION

SYSTEMATIC REVIEW

Current evidence does not support routine use of haloperidol or second-generation antipsychotics for prevention of delirium. There is limited evidence that second-generation antipsychotics may lower the incidence of delirium in postoperative patients!

Annals of Internal Medicine®



2019

TREATMENT

SYSTEMATIC REVIEW

Current evidence does not support routine use of haloperidol or second-generation antipsychotics to treat delirium in adult inpatients.

Annals of Internal Medicine®

HALOPERIDOL & ANTIPYSCHOTICS USE IN THE PREVENTION & TREATMENT OF DELIRIUM IN THE ICU

Summary of Evidence



2018

MIND-USA

The use of haloperidol or ziprasidone, as compared with placebo, in patients with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not significantly alter the duration of delirium..



2019

PREVENTION

SYSTEMATIC REVIEW

Current evidence does not support routine use of haloperidol or second-generation antipsychotics for prevention of delirium. There is limited evidence that second-generation antipsychotics may lower the incidence of delirium in postoperative patients!

Annals of Internal Medicine®



2019

TREATMENT

SYSTEMATIC REVIEW

Current evidence does not support routine use of haloperidol or second-generation antipsychotics to treat delirium in adult inpatients.

Annals of Internal Medicine®



2022

AID-ICU

Among patients in the ICU with delirium, treatment with haloperidol did not lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo!



HALOPERIDOL & ANTIPYSCHOTICS USE IN THE PREVENTION & TREATMENT OF DELIRIUM IN THE ICU

Summary of Evidence

2018

MIND-USA

The use of haloperidol or ziprasidone, as compared with placebo, in patients with acute respiratory failure or shock and hypoactive or hyperactive delirium in the ICU did not significantly alter the duration of delirium..



2019

PREVENTION

SYSTEMATIC REVIEW

Current evidence does not support routine use of haloperidol or second-generation antipsychotics for prevention of delirium. There is limited evidence that second-generation antipsychotics may lower the incidence of delirium in postoperative patients!

Annals of Internal Medicine®

2019

TREATMENT

SYSTEMATIC REVIEW

Current evidence does not support routine use of haloperidol or second-generation antipsychotics to treat delirium in adult inpatients.

Annals of Internal Medicine®

2022

AID-ICU

Among patients in the ICU with delirium, treatment with haloperidol did not lead to a significantly greater number of days alive and out of the hospital at 90 days than placebo!



Current evidence does not support the routine use of antipsychotic medications for the treatment or prevention of delirium in critically ill patients. The findings from clinical trials highlight the importance of individualized patient management, focusing on nonpharmacological interventions and cautious use of antipsychotics when necessary.